Status:
UNKNOWN
Study on Umorestat Hydrogen Sulfate Capsule in Patients With Locally Advanced/Metastatic Pancreatic Cancer
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborating Sponsors:
Sun Yat-sen University
Conditions:
Pharmacokinetics
Pancreatic Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
Based on the tolerability, safety and pharmacokinetics phase I/II clinical trials of ulimostat hydrochloride capsules (LH011) combined with gemcitabine hydrochloride (GEM) in locally advanced/metastat...
Detailed Description
This study is a research on the pharmacokinetics and gene polymorphisms of ulimostat hydrochloride capsules in patients with locally advanced/metastatic pancreatic cancer. Aims to collect the "Phase I...
Eligibility Criteria
Inclusion
- Successfully enrolled in a Phase I/II clinical study on the tolerability, safety and pharmacokinetics of Umorestat hydrogen Sulfate capsule (LH011) combined with gemcitabine hydrochloride (GEM) for patients with locally advanced/metastatic pancreatic cancer.
- Fully understand the purpose and requirements of this study and sign a written informed consent.
- Willing to provide blood samples.
Exclusion
- Suffering from inflammatory bowel disease.
- The researcher considers it unsuitable to participate in this study.
Key Trial Info
Start Date :
June 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT05329597
Start Date
June 24 2020
End Date
July 1 2022
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-Sen Memorial Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510120